UroGen Pharma Ltd. (0XOD)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 34.48 |
|---|---|
| 52-week range | 16.19 – 51.11 |
| Return, 1 month / 3 months | −20.1% / −19.5% |
| Return, 1 year / 3 years | – / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 32 |
| Volatility (1 year) | 60.4% |
| Worst drawdown (1 year) | -34.8% |
| Average daily value traded | 0.06M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UroGen Pharma is a biopharmaceutical company that develops and commercialises treatments for cancers and other diseases of the urinary tract. Its main product is a gel formulation of a chemotherapy drug that is delivered directly into the bladder to treat a type of low-grade bladder cancer, and it is also developing similar treatments for other urothelial conditions. The company is based in Israel and the United States and serves urologists and their patients.
The shares are listed on the London Exchange in UK under the code 0XOD, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UroGen Pharma Ltd. (0XOD) trades on the London Exchange in UK. It last closed at USD 34.48 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,315 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 11.2% | ||
| From 52-week high | -31.7% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -19.5% | ||
| 6-month return | 33.6% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 60.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.8% | ||
| Liquidity | 25 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.06M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −5.7% |
|---|---|
| 1 month | −20.1% |
| 3 months | −19.5% |
| 6 months | +33.6% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 42.25 / 31.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.76 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.